Detalhe da pesquisa
1.
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer.
Nature
; 585(7826): E21, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32887973
2.
The National Lung Matrix Trial of personalized therapy in lung cancer.
Nature
; 583(7818): 807-812, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32669708
3.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer
; 130(3): 400-409, 2024 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864520
4.
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
Annu Rev Med
; 73: 231-250, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644155
5.
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Cancer
; 129(11): 1672-1680, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930815
6.
PARP inhibitors: enhancing efficacy through rational combinations.
Br J Cancer
; 129(6): 904-916, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37430137
7.
Targeting ATR in Cancer Medicine.
Cancer Treat Res
; 186: 239-283, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37978140
8.
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Curr Opin Oncol
; 34(5): 559-569, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35787597
9.
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
Invest New Drugs
; 40(1): 99-105, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34468905
10.
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Invest New Drugs
; 40(2): 290-299, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562230
11.
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
Invest New Drugs
; 40(1): 124-133, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34559346
12.
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response.
Br J Cancer
; 124(5): 857-859, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33328609
13.
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
Br J Cancer
; 125(4): 520-527, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34040174
14.
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.
Oncologist
; 26(7): 588-596, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783054
15.
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.
Oncologist
; 26(11): 925-e1918, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34288257
16.
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
Gynecol Oncol
; 158(3): 570-575, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534809
17.
Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.
Br J Cancer
; 119(9): 1118-1128, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30377337
18.
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Br J Haematol
; 201(3): e25-e29, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951293
19.
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
CA Cancer J Clin
; 61(1): 31-49, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205831
20.
Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.
Radiology
; 284(1): 88-99, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28301311